Validated using a knockout cell lineRecombinantRabMAb

Recombinant Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

Submit a review Submit a question References (5)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR15891] to p18 INK4c/CDKN2C
  • Suitable for: WB, IP, ICC/IF, IHC-P
  • Knockout validated
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-p18 INK4c/CDKN2C antibody [EPR15891]
    See all p18 INK4c/CDKN2C primary antibodies

  • Description

    Rabbit monoclonal [EPR15891] to p18 INK4c/CDKN2C

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IP, ICC/IF, IHC-Pmore details

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Recombinant fragment within Human p18 INK4c/CDKN2C aa 1-150. The exact sequence is proprietary.
    Database link: P42773

  • Positive control

    • WB: HEL-293T, Ramos, HeLa, Jurkat, Rat kidney, Rat spleen and NIH 3T3 lysates. IHC-P: Human brain and glioma tissues; ICC/IF: HeLa cells.

  • General notes

     

     

     This product was previously labelled as p18 INK4c

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab192239 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 18 kDa (predicted molecular weight: 18 kDa).
IP 1/30.
ICC/IF 1/100.
IHC-P 1/50. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Target

  • Function

    Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.

  • Tissue specificity

    Highest levels found in skeletal muscle. Also found in pancreas and heart.

  • Sequence similarities

    Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.
    Contains 4 ANK repeats.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • CDK6 inhibitor p18 antibody
    • CDKN 2C antibody
    • CDKN 6 antibody
    • Cdkn2c antibody
    • CDKN6 antibody
    • CDN2C_HUMAN antibody
    • Cyclin dependent inhibitor antibody
    • Cyclin dependent kinase 4 inhibitor C antibody
    • Cyclin dependent kinase 6 inhibitor antibody
    • Cyclin dependent kinase 6 inhibitor p18 antibody
    • Cyclin dependent kinase inhibitor 2C (p18 inhibits CDK4) antibody
    • Cyclin dependent kinase inhibitor 2C antibody
    • Cyclin-dependent kinase 4 inhibitor C antibody
    • Cyclin-dependent kinase 6 inhibitor antibody
    • INK4C antibody
    • OTTHUMP00000046546 antibody
    • p18 antibody
    • p18 inhibits CDK4 antibody
    • p18 INK4c antibody
    • p18 INK6 antibody
    • p18-INK4c antibody
    • p18-INK6 antibody
    see all

Images

  • Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    All lanes : Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239) at 1/1000 dilution

    Lane 1 : Wild-type HeLa cell lysate
    Lane 2 : CDKN2C knockout HeLa cell lysate
    Lane 3 : Rat Kidney cell lysate
    Lane 4 : Jurkat cell lysate

    Lysates/proteins at 20 µg per lane.

    Performed under reducing conditions.

    Predicted band size: 18 kDa



    Lanes 1-4: Merged signal (red and green). Green - ab192239 observed at 18 kDa. Red - loading control ab8245 observed at 37 kDa.

     ab192239 Anti-p18 INK4c/CDKN2C antibody [EPR15891] was shown to specifically react with Cyclin Dependent Kinase Inhibitor 2C in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265031 (knockout cell lysate ab257887) was used. Wild-type and Cyclin Dependent Kinase Inhibitor 2C knockout samples were subjected to SDS-PAGE. ab192239 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

     

  • Immunocytochemistry/ Immunofluorescence - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Immunocytochemistry/ Immunofluorescence - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

    Immunofluorescent analysis of HeLa cells (4% Paraformaldehyde-fixed, 0.1% tritonX-100 permeabilized) labeling p18 INK4C/CDKN2C with ab192239 at 1/100 dilution (5μg/mL) followed by Goat anti rabbit IgG (AlexaFluor® 488) (ab150077) secondary at 1/200 dilution and counter-stained with DAPI (blue).
    Negative controls: anti-p18 INK4C/CDKN2C at 1/100 dilution, Secondary ab (Goat anti mouse IgG (Alexa Fluor®594)) at 1/400 dilution.

     

  • Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    All lanes : Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239) at 1/1000 dilution

    Lane 1 : Rat kidney lysate
    Lane 2 : Rat spleen lysate
    Lane 3 : NIH 3T3 lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

    Predicted band size: 18 kDa

  • Immunoprecipitation - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Immunoprecipitation - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

    Western blot analysis of immunoprecipitation pellet from HeLa lysate immunoprecipitated using ab192239 at 1/30 dilution.
    Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution.

     

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

    Immunohistochemical analysis of paraffin-embedded Human glioma tissue labeling p18 INK4C/CDKN2C with ab192239 at 1/50 dilution followed by pre-diluted HRP Polymer for Rabbit/Mouse IgG secondary antibody and counter-stained with Hematoxylin. (inset: negative control).

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

    Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling p18 INK4C/CDKN2C with ab192239 at 1/50 dilution followed by pre-diluted HRP Polymer for Rabbit/Mouse IgG secondary antibody and counter-stained with Hematoxylin. (inset: negative control).

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Western blot - Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    All lanes : Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239) at 1/10000 dilution

    Lane 1 : 293 cell lysate
    Lane 2 : Ramos cell lysate
    Lane 3 : HeLa cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

    Predicted band size: 18 kDa

  • Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)
    Anti-p18 INK4c/CDKN2C antibody [EPR15891] (ab192239)

References (5)

Publishing research using ab192239? Please let us know so that we can cite the reference in this datasheet.

ab192239 has been referenced in 5 publications.

  • Liu M  et al. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics 10:4437-4452 (2020). PubMed: 32292506
  • Prikrylova T  et al. 5-hydroxymethylcytosine Marks Mammalian Origins Acting as a Barrier to Replication. Sci Rep 9:11065 (2019). PubMed: 31363131
  • Brock M  et al. Analysis of hypoxia-induced noncoding RNAs reveals metastasis-associated lung adenocarcinoma transcript 1 as an important regulator of vascular smooth muscle cell proliferation. Exp Biol Med (Maywood) 242:487-496 (2017). PubMed: 28056547
  • Zhang S  et al. lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence. J Urol 196:1270-8 (2016). PubMed: 27267320
  • Wang L  et al. Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma. Mol Med Rep 13:243-8 (2016). PubMed: 26573508

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab192239.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com